No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 27 of the 40 quarters in the window, leaving 13 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Tempest Therapeutics, Inc. (TPST) stock was $0.79 as of Oct 6, 2026, 4:00 PM EDT, down 0.64% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -92.3% · 3-year avg -38.8%/yr · 5-year avg -66.8%/yr
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer.
Biotechnology · Brisbane, CA
Next Earnings Date
Nov 4, 2026
29 days away
EPS Estimate
-0.32
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.34
vs Estimate
$-0.30
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1TPST | $12.58M | $0.79 | -0.64% | -92.28% | -66.75% | -64.11% | N/A |
| 2DARE | $12.48M | $0.83 | -1.19% | -61.15% | -46.35% | -39.10% | vs TPST |
| 3PASG | $12.69M | $3.95 | -3.42% | -48.39% | -53.23% | N/A | vs TPST |
| 4BFRG | $12.78M | $0.69 | +15.99% | -58.58% | N/A | N/A | vs TPST |
| 5CTSO | $12.79M | $4.07 | +2.65% | -79.67% | -52.26% | -28.72% | vs TPST |
| 6LTRN | $12.17M | $0.95 | +1.45% | -76.97% | -37.05% | N/A | vs TPST |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 1 analyst
Average Price Target
$7.00
+788.9% upside
Low
$7.00
Current
$0.79
High
$7.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.32 | $-0.32 | $-0.32 | 1 |
| Quarter ending Dec 2026 | $-0.29 | $-0.29 | $-0.29 | 1 |
| Quarter ending Mar 2027 | $-6.99 | $-6.99 | $-6.99 | 1 |
| Quarter ending Jun 2027 | $-7.03 | $-7.03 | $-7.03 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-2.85 | $-2.85 | $-2.85 | 1 |
| FY 2027 | $-0.90 | $-0.90 | $-0.90 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $17.85M | $17.85M | $17.85M | 1 |
| FY 2027 | $57.82M | $57.82M | $57.82M | 1 |
